Call Us for Support
+91 9654860915
Google Reviews
4.8
Call Us for Support
+91 9654860915
Sourced directly from the authorized manufacturer network to ensure authenticity and quality.
Ready to proceed? Start a request for Veozah on our secure patient portal to submit your prescription, upload documents and track your approval status.
Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.
Manufacturer / Innovator:
USA
Regulatory Approval:
Your Trustworthy Partner For Named Patient Program
Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.
100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.
Medicines sourced from authorized manufacturers with full batch traceability.
EU-GDP compliant warehousing for secure, quality-controlled global distribution.
Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.
Veozah (fezolinetant) is a neurokinin 3 (NK3) receptor antagonist approved by the FDA for the treatment of moderate to severe vasomotor symptoms (hot flashes) due to menopause.
Veozah blocks the NK3 receptor in the brain's temperature-regulation center, helping to rebalance the neuronal activity that becomes disrupted by declining estrogen levels during menopause and drives hot flashes and night sweats. Unlike hormone therapy, Veozah works through a non-hormonal mechanism.
Veozah is intended for women experiencing moderate to severe vasomotor symptoms associated with menopause who are seeking a non-hormonal treatment option.
The recommended dose of Veozah is 45 mg taken orally once daily, at approximately the same time each day, with or without food.
Boxed Warning — Veozah: Hepatotoxicity has occurred with the use of Veozah in the postmarketing setting. Hepatic laboratory tests should be performed prior to initiation of treatment. Veozah should not be started if either aminotransferase level is 2 times the upper limit of normal or greater, or if total bilirubin is 2 times the upper limit of normal or greater.
Follow-up hepatic laboratory testing is recommended monthly for the first three months of treatment, and again at months six and nine.
Veozah should be discontinued immediately if transaminase levels exceed 5 times the upper limit of normal, or exceed 3 times the upper limit of normal accompanied by a total bilirubin greater than 2 times the upper limit of normal.
Veozah is contraindicated in patients with known cirrhosis, severe renal impairment or end-stage renal disease, and when used with CYP1A2 inhibitors.
Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.
Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.
Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.
Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.
Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant conditions to maintain product integrity.
Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.
Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.
Veozah is manufactured and marketed by Astellas US LLC. It is sourced through authorized distribution channels for patients seeking named-patient import into India.
Patients typically need a valid prescription from a treating gynecologist or physician confirming menopause diagnosis and symptom severity. NPP's regulatory team assists in preparing and verifying the documentation needed for a compliant import.
As an FDA-approved non-hormonal therapy for menopausal vasomotor symptoms, Veozah is sourced through authorized channels and imported under GDP-compliant logistics to preserve product quality throughout transit.
NPP sources Veozah directly from authorized pharmaceutical distributors to ensure product authenticity and full traceability. Every shipment is handled under Good Distribution Practice (GDP) conditions from origin to the patient's doorstep.
Veozah should be stored at 20°C to 25°C, with excursions permitted between 15°C and 30°C, and this condition is maintained throughout transit.
Once documentation and regulatory approvals are in place, delivery timelines are communicated transparently at the time of quotation, accounting for import clearance and last-mile logistics to the patient's city.
Patients across India can access Veozah through NPP's regulated import pathway, with gynecology specialists in major cities supporting the treatment process.
Leading hospitals in Mumbai support menopause care coordination and documentation for Veozah access.
Delhi's major hospitals assist patients with prescription support and documentation for Veozah.
Bangalore's specialist network offers access coordination for eligible patients seeking Veozah.
Chennai-based gynecology specialists coordinate Veozah access alongside comprehensive menopause care.
Hyderabad's care institutions support patients pursuing Veozah therapy.
Kolkata's specialist centers help coordinate documentation and treatment access for Veozah.
Pune-based specialists assist with prescription support and Veozah treatment planning.
Ahmedabad's specialty hospitals support the import and treatment process for Veozah.
Kochi's specialist units assist patients with the documentation needed for Veozah access.
Chandigarh's care centers support Veozah treatment coordination for patients from North India.
Jaipur's specialists help patients navigate the Veozah access process.
Lucknow-based centers assist patients pursuing Veozah therapy.
Bhubaneswar's institutions support access to Veozah for eligible patients.
Guwahati's specialists help coordinate Veozah access for patients across the Northeast.
Patients in other cities across India can also access Veozah through NPP's nationwide coordination network.
Last Updated: 15 September 2026
Our specialists are here to guide you through every step of the medicine access process.
Mail Us At:
info@namedpatientprogram.comContact Us:
+91 9654860915Send us a message
